Partner. Advocate. Friend. At the MPN Research Foundation, we’re committed to standing with you in the fight against polythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF) – the group of blood cancers collectively known as myeloproliferative neoplasms.
NCCN Guidelines document evidence-based consensus-driven management to ensure that all patients receive preventive, diagnostic, treatment, and supportive care services that are most likely to lead to optimal outcomes.Read More
CTI BIOPHARMA Announces top-line results from PERSIST-2 Phase 3 trial of Pacritnib for high-risk patients with advanced myelofibrosisRead More
PMF is a chronic blood cancer in which excessive scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells.Learn about PMF
Most commonly diagnosed in women over the age of 50, ET is associated with a proliferation of platelet precursors in the bone marrow and complications frequently include blood clotting and/or bleeding.Learn about ET
The disease is most common in men over the age of 60, but anyone can develop PV. PV patients typically experience an elevated red blood cell count, an elevated platelet count and an enlarged spleen, especially over time.Learn about PV
Juan Alderete, PV 06
Take a moment to read our "Know your MPN" ET infographic. We hope you will use this as a tool to educate yourself, family & friends about MPNs